Get startedLog in
    Picture of Eli Lilly and logo

    LLY — Eli Lilly and News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer

    Picture of Eli Lilly and logoEli Lilly and
    13/10/2026 13:15
    BRIEF-Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
    Oct 13 (Reuters) - Prelude Therapeutics Incorporated PRLD.O:
    • PRELUDE ANNOUNCES CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH LILLY TO EVALUATE KAT6A SELECTIVE DEGRADER PRT13722 IN COMBINATION WITH VERZENIO® AND INLURIYO® IN PATIENTS WITH HR+/HER2- BREAST CANCER
    • PRELUDE THERAPEUTICS INCORPORATED - AGREEMENT SUPPORTS EVALUATION OF PRT13722 WITH ABEMACICLIB AND IMLUNESTRANT IN PHASE 1 TRIAL
    • PRELUDE THERAPEUTICS INCORPORATED - EXPECTS TO BEGIN ENROLLMENT FOR PHASE 1 TRIAL IN Q4 2026
    • PRELUDE THERAPEUTICS INCORPORATED - MAINTAINS FULL GLOBAL DEVELOPMENT AND COMMERCIAL RIGHTS TO PRT13722
    Source text: ID:nGNX97sbVy
    Further company coverage: PRLD.O

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Eli Lilly and

    See all news